GKL-006Allo

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug NameGKL-006Allo
Drug Alias NameGKL-006AlloGKL006Allo
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > NKT cell therapy > Invariant natural killer T cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionAnti-Glypican-3
TargetsGlypican-3
Therapy Area/IndicationsSolid tumoursSpondylitis, AnkylosingNeoplasm Metastasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBeijing Gene Key Life Technology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesBeijing Gene Key Life Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursSpondylitis, AnkylosingNeoplasm Metastasis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A